Figure 1.

Model representation of cumulative incidence of prostate cancer death for watchful waiting and radical prostatectomy groups in the absence of screening, mimicking Scandinavian Prostate Cancer Group Study Number 4 A) and in the presence of prostate-specific antigen screening B), based on a model that incorporates lead time and overdiagnosis in a manner consistent with the fraction of case patients in Prostate Cancer Intervention Versus Observation Trial that were screen detected.